Time to progression · patients with non‐muscle invasive bladder cancer
Intravesically administered BCG alternating with IFN‐α showed no clear difference in time‐to‐progression compared with intravesically administered BCG alone (low certainty).
1 finding from 1 review
Discontinuation of medication due to adverse events · patients with non‐muscle invasive bladder cancer
Intravesically administered BCG alternating with IFN‐α showed no clear difference in discontinuation of therapy due to adverse events compared with intravesically administered BCG alone (low certainty).
1 finding from 1 review
Disease‐specific mortality ‐ not reported · patients with non‐muscle invasive bladder cancer
Intravesically administered BCG alternating with IFN‐α showed no clear difference in disease‐specific mortality compared with intravesically administered BCG alone (low certainty).
1 finding from 1 review
Intervention not reported
Variceal bleeding 5 years · patients with chronic hepatitis C who have failed prior antiviral therapy and who have severe histologic disease (grade 3 or 4 fibrosis)…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Ascites 5 years · patients with chronic hepatitis C who have failed prior antiviral therapy and who have severe histologic disease (grade 3 or 4 fibrosis)…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
First recurrence · high‐risk melanoma participants
The intervention leads to lower first recurrence (high certainty).
1 finding from 1 review
Intervention not reported
Death · high‐risk melanoma participants
The intervention leads to lower death (high certainty).
1 finding from 1 review
Intervention not reported
Sustained (6 months) EDSS increase after 3 years · patients with secondary progressive multiple sclerosis
The intervention showed no clear difference in sustained (6 months) EDSS increase after 3 years (high certainty).
1 finding from 1 review
Intervention not reported
Sustained (3 months) EDSS increase after 3 years · patients with secondary progressive multiple sclerosis
The intervention leads to lower sustained (3 months) EDSS increase after 3 years (high certainty).
1 finding from 1 review
Intervention not reported
Sustained (3 or 6 months) EDSS increase at 3 years in patients with pre study relapses · patients with secondary progressive multiple sclerosis
The intervention showed no clear difference in sustained (3 or 6 months) EDSS increase at 3 years in patients with… (high certainty).
1 finding from 1 review
Intervention not reported
Number of patients with at least one relapse during · patients with secondary progressive multiple sclerosis
The intervention leads to lower number of patients with at least one relapse during (high certainty).
1 finding from 1 review
Intervention not reported
Patients with progression of the disease ( · patients with Primary Progressive Multiple Sclerosis
The intervention showed no clear difference in patients with progression of the disease ( (high certainty).
1 finding from 1 review
Intervention not reported
Patients with severe adverse event ( · patients with Primary Progressive Multiple Sclerosis
The intervention showed no clear difference in patients with severe adverse event ( (high certainty).
1 finding from 1 review
Intervention not reported
Patients with any related adverse event ( · patients with Primary Progressive Multiple Sclerosis
The intervention leads to higher patients with any related adverse event ( (high certainty).
1 finding from 1 review
Intervention not reported
Mean EDSS change at two years ( · patients with Primary Progressive Multiple Sclerosis
1 finding from 1 review
Intervention not reported
Sustained increase in spasticity ( · patients with Primary Progressive Multiple Sclerosis
The intervention showed no clear difference in sustained increase in spasticity ( (high certainty).
1 finding from 1 review